Brentuximab Vedotin (BV) in Combination with Lenalidomide (len) and Rituximab (R) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Results from the Phase 3 ECHELON-3 Study
Journal of Clinical Oncology(2024)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined